Cencora Inc Dossier - Source-backed chat

Cencora Inc

CORNYSE

SectorHealth Care

IndustryHealth Care Distributors

Beta (adjusted)0.71

Intrinsic Value $291.78median of 6 methods · middle span $225-$504based on filings through 30 Jun 2026

Market Price $309.78Price as of 1 Oct 2026

Near fair valueIntrinsic value is 6% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $59.1B

Enterprise Value $68B

Shares Outstanding 194.9M diluted

Moat Rating Wide

Next Earnings Date4 Nov 2026

Last ex-dividend14 Aug 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cencora combines resilient pharmaceutical-distribution demand with expanding specialty-care capabilities. Fiscal third-quarter 2026 revenue grew 5.1%, adjusted operating income grew 17.0%, and adjusted diluted EPS grew 12.0%. Management consequently raised fiscal 2026 adjusted EPS guidance to $17.75-$17.95 and expects adjusted operating-income growth of 13%-14%. The principal offsets are acquisition-related leverage, approximately $490 million of expected net interest expense, integration demands from OneOncology and other specialty investments, customer losses, and the lower gross margins associated with GLP-1 sales. At the issuer-reported August 28 closing price of $322.03, the independently developed base-case target supports a Buy view.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$330.00

Mean target$372.58

High · most bullish analyst$430.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$260.0020%

Acquisition integration proves more costly than expected, higher interest expense constrains capital allocation, lower-margin GLP-1 mix limits profitability, customer losses persist and adjusted free cash flow misses the approximately $3.0 billion outlook. Under this outcome, confidence in the long-term growth framework deteriorates.

Base CaseCentral scenario

$372.5855%

Matches the consensus mean

Cencora delivers fiscal 2026 results within its updated guidance, integrates OneOncology without material disruption, maintains pharmaceutical-volume growth and converts its specialty strategy into continued earnings growth. The $370 target is an independent scenario estimate informed by the issuer's $322.03 August 28 closing price, $17.75-$17.95 fiscal 2026 adjusted EPS guidance and 10%-14% long-term adjusted EPS-growth framework.

Bull CaseUpside scenario

$420.0025%

Specialty investments, including OneOncology, produce sustained operating leverage; U.S. Healthcare Solutions remains near the upper end of guidance; international and specialty-logistics momentum persists; and cash generation supports debt reduction alongside repurchases. This outcome assumes performance at or above the upper end of the company's long-term adjusted EPS-growth framework.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Fiscal third-quarter 2026 adjusted operating income grew 17.0% and adjusted diluted EPS grew 12.0%, demonstrating earnings growth ahead of revenue growth.
OneOncology and Retina Consultants of America deepen Cencora's specialty and physician-services exposure, while management targets long-term adjusted operating-income growth of 7%-10% and adjusted EPS growth of 10%-14%.
Cencora repurchased $1 billion of shares during the third fiscal quarter, retains a $2 billion repurchase authorization and declared a $0.60 quarterly dividend.

Key Investment Risks

Long-term debt was $11.44 billion at June 30, 2026, versus $7.54 billion at September 30, 2025, and fiscal 2026 net interest expense is expected to be approximately $490 million.
Management identified lower-margin GLP-1 sales, the prior loss of an oncology customer and lower sales to a large mail-order customer as offsets to U.S. Healthcare Solutions performance.
The OneOncology acquisition materially increased operating expenses, while ongoing acquisition, divestiture and restructuring activity increases integration and execution complexity.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.